D-Index & Metrics Best Publications

Nathanael S. Gray

Stanford University
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Biology and Biochemistry D-index 129 Citations 69,577 762 World Ranking 299 National Ranking 211

Overview

What is he best known for?

The fields of study Nathanael S. Gray is best known for:

Dopamine
Amphetamine
Sphingosine-1-phosphate

Nathanael S. Gray conducts interdisciplinary study in the fields of Pharmacology and Neuroscience through his research. He performs multidisciplinary studies into Neuroscience and Pharmacology in his work. As part of his studies on Internal medicine, he often connects relevant subjects like G protein-coupled inwardly-rectifying potassium channel. Nathanael S. Gray merges G protein-coupled inwardly-rectifying potassium channel with G protein in his research. Nathanael S. Gray merges G protein with Receptor in his research. His research on Receptor often connects related areas such as Sphingosine-1-phosphate. In his works, Nathanael S. Gray performs multidisciplinary study on Sphingosine-1-phosphate and Sphingosine. The study of Sphingosine is intertwined with the study of Sphingosine-1-phosphate receptor in a number of ways. The study of Sphingosine-1-phosphate receptor is intertwined with the study of Internal medicine in a number of ways.

His most cited work include:

Abolition of latent inhibition by a single 5 mg dose ofd-amphetamine in man (249 citations)
The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rate (237 citations)
Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET (211 citations)

What are the main themes of his work throughout his whole career to date

Many of his research projects under Leukemia are closely connected to Cancer research with Cancer research, tying the diverse disciplines of science together. The study of Immunology is intertwined with the study of Leukemia in a number of ways. Nathanael S. Gray connects Cancer research with Genetics in his study. His Genetics study frequently draws connections between related disciplines such as Cell culture. Nathanael S. Gray integrates several fields in his works, including Cell culture and Gene. Nathanael S. Gray integrates many fields in his works, including Gene and Downregulation and upregulation. Pharmacology and Developmental psychology are fields of study that intersect with his Neuroscience study. Nathanael S. Gray integrates Pharmacology and Psychiatry in his studies. His research on Psychiatry frequently connects to adjacent areas such as Schizophrenia (object-oriented programming).

Nathanael S. Gray most often published in these fields:

Neuroscience (46.67%)
Internal medicine (46.67%)
Psychiatry (40.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Targeting cancer with small molecule kinase inhibitors

Jianming Zhang;Priscilla L. Yang;Nathanael S. Gray.
Nature Reviews Cancer (2009)

2804 Citations

Systematic identification of genomic markers of drug sensitivity in cancer cells

Mathew J. Garnett;Elena J. Edelman;Sonja J. Heidorn;Christopher Greenman;Christopher Greenman.
Nature (2012)

2279 Citations

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Carson C. Thoreen;Seong A. Kang;Jae Won Chang;Qingsong Liu.
Journal of Biological Chemistry (2009)

1735 Citations

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.

Aravind Subramanian;Rajiv Narayan;Steven M. Corsello;Steven M. Corsello;David D. Peck.
Cell (2017)

1662 Citations

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

Timothy R. Peterson;Mathieu Laplante;Carson C. Thoreen;Yasemin Sancak.
Cell (2009)

1398 Citations

A unifying model for mTORC1-mediated regulation of mRNA translation

Carson Thoreen;Lynne Chantranupong;Lynne Chantranupong;Heather R. Keys;Heather R. Keys;Tim Wang.
Nature (2012)

1346 Citations

A Landscape of Pharmacogenomic Interactions in Cancer

Francesco Iorio;Francesco Iorio;Theo A. Knijnenburg;Theo A. Knijnenburg;Daniel J. Vis;Graham R. Bignell.
Cell (2016)

1247 Citations

A chemical switch for inhibitor-sensitive alleles of any protein kinase

Anthony C. Bishop;Jeffrey A. Ubersax;Dejah T. Petsch;Dina P. Matheos.
Nature (2000)

1179 Citations

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

Jussi P. Koivunen;Craig Mermel;Kreshnik Zejnullahu;Carly Murphy.
Clinical Cancer Research (2008)

1133 Citations

Rational design of inhibitors that bind to inactive kinase conformations.

Yi Liu;Nathanael S Gray.
Nature Chemical Biology (2006)

1121 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Nathanael S. Gray